RANBAXY

  • Andhra HC lifts stay on merger between Ranbaxy, Sun Pharma May 24, 2014

    The Andhra Pradesh High Court on Saturday vacated a status quo order it had issued earlier on Sun PharmaRanbaxy merger process, paving the way for the pharma giants becoming a single entity. While vacating the status quo, Justice G Chandraiah also disposed of the petition filed by two investors requesting the...
  • Andhra Pradesh HC verdict on Sun PharmaRanbaxy merger plea on Saturday May 23, 2014

    Hyderabad: The Andhra Pradesh High Court will on Saturday decide on the petition filed by two investors requesting it to restrain the BSE and NSE from giving any clearance to the scheme of amalgamation or merger between Sun Pharma and Ranbaxy. After hearing the arguments from the counsels of the petitioners,...
  • SC asks Andhra HC to decide on RanbaxySun Pharma merger May 21, 2014

    New Delhi: The Supreme Court on Wednesday asked the Andhra Pradesh High Court, which had passed an interim order staying the $4 billion merger of Ranbaxy with Sun Pharma, to decide the issue within two days. Hearing appeals filed by Sun Pharmaceutical, Ranbaxy Laboratories and Daiichi Sankyo Company against HC interim...
  • News 360: Huge turnout on first poll phase in Assam, Tripura April 7, 2014

    An estimated 72 per cent of the 64.4 lakh voters exercised their franchise peacefully in five Lok Sabha constituencies in Assam sealing the electoral fate of 51 contestants, including two union ministers in the first phase. ...
  • Sun Pharma to buy Ranbaxy in $3.2 billion deal April 7, 2014

    Tokyo: Sun Pharmaceutical Industries Ltd said it will buy generic drug maker Ranbaxy Laboratories Ltd, which has hit regulatory snags in its key US market over quality issues, in an all-share deal with total equity value of $3.2 billion. Ranbaxy, India's No.1 drugmaker by sales and 63.4 per cent held by...
  • SC notice to Centre, Ranbaxy on plea against adulterated drugs March 14, 2014

    New Delhi: There is more trouble for pharma giant Ranbaxy. The Supreme Court has issued a notice to the company as well as the Centre on the basis of a petition that has sought a probe against Ranbaxy for allegedly supplying adulterated drugs in the country. The apex court has,...
  • Ranbaxy suspends drug ingredients shipment from 2 plants February 25, 2014

    Tokyo: Drugmaker Ranbaxy Laboratories Ltd on Tuesday said it has suspended all shipments of pharmaceutical ingredients produced at two local factories to review processes and controls. The Toansa and Dewas plants are currently banned from shipping products to the United States following quality concerns, so the suspension will hit supplies to...
  • US 'not targeting' India companies: FDA February 22, 2014

    The United States is "not targeting" Indian companies, but has a strict quality control regime for all products being imported into America, the head of the US Food and Drug Administration said on Saturday. "We are not targeting Indian companies. We are undertaking our required regulatory activities. We inspect and take...
  • FDA prohibits Ranbaxy products in US January 24, 2014

    In a setback to Indian pharmaceutical giant Ranbaxy, the US has prohibited it from producing and distributing "substandard quality" drugs for the American market from its Toansa facility in Punjab. In an order, the Food and Drug Administration on Thursday prohibited Ranbaxy from distributing in the US the drugs manufactured using...
  • USFDA bans drugs from Ranbaxy's Toansa API plant January 24, 2014

    The US Food and Drug Administration (USFDA) has banned Ranbaxy's Punjabbased Toansa Active Pharmaceutical Ingredients (API) plant. "Ranbaxy Laboratories is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDAregulated drug products. The Toansa facility is now subject to certain terms of a...
  • Suspected hair in a Ranbaxy tablet led to US import alert September 18, 2013

    During a visit to a facility of leading drugmaker Ranbaxy Laboratories Ltd last year, US inspectors found that a black fibre embedded in a tablet may have been a hair from an employee's arm, according to documents seen by Reuters. That and other quality concerns led the US Food and Drug...
  • US FDA bans imports from Ranbaxy's Mohali plant September 16, 2013

    Mumbai: The US Food and Drug Administration has issued an import alert against drugs manufactured at Ranbaxy's Mohali plant in Punjab over quality concerns. This means Ranbaxy will not be able to ship drugs manufactured at the plant to the US until the ban is lifted. This is the third...
  • Adulterated drugs: Evidence against Ranbaxy likely to be furnished in SC August 12, 2013

    New Delhi: Evidence in a case against Ranbaxy is likely to be furnished in the Supreme Court on Monday. Earlier in August, the Supreme Court while replying to a petition seeking cancellation of Ranbaxy's manufacturing licence had said that the petitioner can file the documents to prove that the company...
  • 9 pharmaceutical companies fined Rs 2500 cr for overcharging July 19, 2013

    New Delhi: Nine pharmaceutical companies have been fined Rs 2500 crore by the National Pharmaceutical Pricing Authority (NPPA) for overcharging customers. The NPPA imposed penalty after the drug makers, which also include Ranbaxy, Dr. Reddy's Lab, Glenmark, Cipla and Cadilla, were overcharging patients on Doxofylline. The asthma drug was being...
  • Adulterated drugs: SC dismisses PIL against Ranbaxy June 25, 2013

    New Delhi: The Supreme court on Tuesday dismissed a PIL against Ranbaxy. The court in its order said that there is no evidence to show that the pharma giant manufactured substandard drugs. The apex court also said that the petitioner failed to bring in evidence against Ranbaxy. The PIL was filed...
  • EU fines Ranbaxy, others for blocking cheaper drugs June 19, 2013

    Brussels: European antitrust regulators fined nine drug makers, including Denmark's Lundbeck and India's Ranbaxy, a total of 146 million euros for blocking the supply of a cheaper antidepressant to the market, the first EU sanction against such deals. The punishments follow a 2009 report by the European Commission on the pharmaceutical...
  • Ranbaxy should improve on compliance: Vikas Dandekar June 11, 2013

    The Supreme Court will hear a PIL on Tuesday seeking a ban on Ranbaxy drugs. The petitioner cited the pharma giant's case in the US where Ranbaxy USA admitted to selling substandard and adulterated drugs. The pharma giant has been asked to pay a fine of 500 million dollars. Ranbaxy...
  • SC to hear PIL seeking a ban on Ranbaxy drugs today June 11, 2013

    New Delhi: The Supreme Court will hear a PIL on Tuesday seeking a ban on Ranbaxy drugs. The petitioner cited the pharma giant's case in the US where Ranbaxy USA admitted to selling substandard and adulterated drugs. The pharma giant was asked to pay a fine of 500 million...
  • Apollo Pharmacy resumes selling Ranbaxy drugs June 10, 2013

    Mumbai: Apollo Pharmacy started selling Ranbaxy drugs at its stores again on Monday after the company recertified its stocks. Apollo Pharmacy had on Friday issued a cautionary advisory against Ranbaxy drugs and had temporarily suspended their sale. Earlier, Mumbai's Jaslok Hospital had also stopped the use of Ranbaxy drugs. "Our...
  • Hospitals, chemists to wait for regulatory word on Ranbaxy June 9, 2013

    New Delhi: Drug regulator DGCI is conducting a "focussed scrutiny" of medicines sold by Ranbaxy and some other drugmakers, but says it remains confident of the quality standards of Indian medicines despite concerns raised by US authorities over some of Ranbaxy's products. While the company continues to assert that its drugs...
  • Apollo Pharmacy issues advisory against Ranbaxy drugs June 7, 2013

    Mumbai: Apollo Pharmacy on Friday issued a cautionary advisory against Ranbaxy drugs and temporarily suspended their sale. Earlier, Mumbai's Jaslok Hospital had stopped the use of Ranbaxy drugs. "Our medical committee, which is a very strong committee within Apollo, has reviewed the matter and recommended, as a cautionary measure, we should...
  • Ranbaxy CEO says the pharma company's medicines have always been safe June 6, 2013

    Under attack for manufacturing spurious drugs, Ranbaxy CEO Arun Sawhney told CNNIBN that Ranbaxy medicines are completely safe and that his company has resumed supplying medicines to Jaslok Hospital in Mumbai. ...
  • India @ 9 with Rajdeep Sardesai June 5, 2013

    Gujarat Chief Minister Narendra Modi on Wednesday dared the government to arrest him in the Ishrat Jahan fake encounter case, according to sources. Sources say that Modi indirectly warned the government not to misuse the CBI. ...
  • News 360: Modi opposes NCTC, accusing Centre of playing big brother June 5, 2013

    While Gujarat Chief Minister Narendra Modi opposes the proposed NCTC, accusing the Centre of playing big brother, the government launches its counter attack saying Modi wants to bring back POTA and TADA back. ...
  • Ranbaxy drugs are 'safe and efficacious': S African regulator June 5, 2013

    Johannesburg: Generic drugs distributed in South Africa by Indian pharmaceutical giant Ranbaxy are "safe" and "efficacious", the country's regulator body said today, days after the beleaguered drug maker paid a fine of USD 500 million in the US for selling adulterated drugs there. "We are confident that drugs currently on...
  • Adulterated drugs: Mumbai hospital stops Ranbaxy products June 5, 2013

    Mumbai: In more trouble for pharma giant Ranbaxy, one of Mumbai's top hospitals asked its consultants to stop buying its products over the adulterated drugs controversy. Mumbai's Jaslok hospital asked its consultants to stop prescribing Ranbaxy products on Wednesday after the company agreed to pay $ 500 million in settlement...
  • Ranbaxy case: Should Indian patients worry over substandard drugs? June 5, 2013

    Mumbai: India exports drugs worth more than 15 billion dollars every year, a majority of which are USbound. Questions are being raised about the standards and quality, after Ranbaxy's whopping 500 million dollar settlement with the US government. The generic drugs in question were manufactured at Ranbaxy's plants in Paonta...
  • PIL in SC against Ranbaxy for manufacturing adulterated drugs June 5, 2013

    New Delhi: A Publicinterest litigation (PIL) has been moved in the Supreme Court against Ranbaxy Pharma. The PIL is seeking prosecution of all Ranbaxy directors and sealing of its manufacturing units at Paonta Sahib and Devas. This was based on Ranbaxy USA's 500 million dollar settlement with the US for...
  • EU to fine Ranbaxy, others for blocking generic drugs June 4, 2013

    Brussels: A European regulator will fine Denmark's Lundbeck, India's Ranbaxy and seven other makers of generic drugs for limiting the supply of cheaper medicines, two people with knowledge of the matter said, its first sanction against "payfordelay" deals. Following an inquiry launched in 2009, the European Union's antitrust regulator will impose...
  • US: Ranbaxy shares down on $ 500 mn fine May 14, 2013

    Mumbai: Ranbaxy Laboratories Ltd shares were down over 1 per cent in early trade on Tuesday after the generic drugmaker pleaded guilty to US felony charges related to drug safety and will pay $500 million in civil and criminal fines. The settlement is its largestever with a generic drugmaker over drug...